Huntsman Cancer Institute at the University of Utah is a national leader in cancer discovery and innovation. Phase 1 clinical trials are the foundation of progress in oncology, transforming scientific ...
HAYA Therapeutics Announces First Cohort Dosed in Phase 1 Trial of HTX-001, an Investigational Cellular Reprogramming Therapy ...
SynOx Therapeutics completed enrollment for the phase 3 TANGENT study of emactuzumab for tenosynovial giant cell tumors, with results expected in 2026. ALX Oncology launched a phase 1 trial of ALX2004 ...
OP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed and no discontinuations due to treatment-related adverse ...
VANCOUVER, Wash., May 13, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI) a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced ...
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the ...
GERMANTOWN, Md., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), an immunology and inflammation (“I&I”) company focused on ...
Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ZB021 in healthy volunteers and to establish proof-of-concept in patients with plaque psoriasis - ...
Accent Therapeutics, a clinical-stage biopharmaceutical company pioneering novel small molecule precision cancer therapies, ...
A seminal paper by Miller and Brody [1] clearly laid the general framework on why we should abandon the term "clinical equipoise" in research. Their paper argued that the concept of equipoise (also ...
Carrie Madormo, RN, MPH, is a health writer. She has over a decade of experience as a registered nurse, practicing in a variety of fields, such as pediatrics, oncology, chronic pain, and public health ...
A Texas Tech University Health Sciences Center researcher received a $1.4 million grant to expand access to pediatric cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results